← Back to searchRecruitingRecruiting
Allograft Dysfunction in Heart Transplant
NCT03102125 · University of California, San Diego
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients
About this study
Adult heart-transplant patients, excluding those with a GFR less than 30 mL/min/1.73m2, contraindications to MRI and allergies to either regadenoson or gadolinium contrast, will be enrolled over 60 months. Patients will be recruited from UCSD. The investigators will specifically enroll all eligible heart-transplant patients.
Brief protocol:
Cardiac MRI is performed. Cine images in standard views are obtained. T1 and T2 mapping sequences are performed on short axis images pre- and post-gadolinium contrast. For stress imaging, intravenous regadenoson is given as a 0.4 mg bolus followed by a 5 mL saline flush. After 30 seconds, short-axis images are acquired for 30 consecutive heartbeats with administration of gadolinium. Rest imaging is performed 30 minutes after stress imaging. Lastly, late gadolinium enhancement images are obtained in standard views. Images are analyzed offline by a blinded independent reader. Patients will be followed for at least 1 year after enrollment for MACE.
Peripheral blood and endomyocardial biopsies will also be collected, timing as per usual clinical care as well as for-cause, for single cell RNAseq analyses.
Eligibility criteria
Inclusion Criteria:
* Age greater than or equal to 18 years old.
* At least three months status post heart transplantation.
Exclusion Criteria:
* Biopsy proven acute rejection episode in the past 3 months.
* Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months.
* Uncontrolled obstructive ventilatory disease including asthma and COPD.
* History of generalized tonic-clonic seizures.
* Second or third degree AV nodal block.
* Sinus node dysfunction.
* Contraindications to MRI including cardiovascular implantable electronic devices.
* Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m2.
* Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine or dipyridamole will be assessed on a case-by-case basis.
* Systolic blood pressure greater than 180 or less than 85 mmHg.
* Diastolic blood pressure greater than 120 or less than 40 mmHg.
* Resting heart rate greater than 120 or less than 45 beats per minute. - Severe claustrophobia.
Study design
Enrollment target: 376 participants
Allocation: non_randomized
Masking: single
Age groups: adult, older_adult
Timeline
Starts: 2019-10-01
Estimated completion: 2025-12-02
Last updated: 2025-02-17
Interventions
Drug: Regadenoson
Primary outcomes
- • Myocardial Perfusion Reserve (60 months)
Sponsor
Paul Kim · other
Contacts & investigators
ContactPaul Kim, MD · contact · pjk017@ucsd.edu · 8582460638
InvestigatorPaul Kim, MD · principal_investigator, UC San Diego
All locations (1)
UC San DiegoRecruiting
La Jolla, California, United States